MedPath

Scienture Launches REZENOPY, Most Potent Naloxone Nasal Spray for Opioid Overdose Treatment

• Scienture Holdings has secured exclusive U.S. rights to launch REZENOPY, a 10mg naloxone HCl nasal spray, marking the highest-strength opioid overdose treatment available in the market.

• Through collaboration with Kindeva Drug Delivery, REZENOPY will be manufactured and distributed, addressing the growing opioid crisis with annual naloxone market sales reaching $189 million.

• The FDA-approved treatment offers enhanced effectiveness against potent opioids, featuring a quick-acting nasal delivery system designed for emergency overdose situations.

Scienture Holdings, Inc. (NASDAQ: SCNX) has announced a definitive agreement to launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, the most potent naloxone treatment available for opioid overdose emergencies. The FDA-approved medication, which received clearance on April 19, 2024, will be exclusively distributed in the United States through a strategic partnership with Kindeva Drug Delivery L.P.

Strategic Partnership and Market Position

The collaboration positions Kindeva as the manufacturer and commercial supplier of REZENOPY®, while Scienture maintains ownership of the new drug application (NDA) and manages sales, marketing, and distribution operations. This arrangement leverages Kindeva's manufacturing expertise and Scienture's commercial infrastructure to address the urgent need for powerful opioid antagonist treatments.
Current market data from IQVIA reveals significant demand, with naloxone products generating $189 million in annual sales and reaching 10 million units distributed across the United States as of December 2024.

Enhanced Treatment Capabilities

REZENOPY® represents a significant advancement in overdose prevention, offering the highest available concentration of naloxone HCl in a nasal spray format. The treatment is designed for immediate administration in emergency situations where opioids may be present, targeting both respiratory and central nervous system depression in adults and pediatric patients.
"Through this collaboration with a well established and strong partner like Kindeva, we now offer REZENOPY®, a higher dose naloxone HCl option for communities, reinforcing our mission to deliver impactful healthcare solutions," stated Narasimhan Mani, Ph.D., MBA, President of Scienture, LLC.

Clinical Application and Administration

The treatment protocol involves intranasal administration, with each package containing two single-spray devices. Healthcare providers can administer a second dose after 2-3 minutes if the initial response is inadequate or if symptoms return. The nasal delivery system has been engineered for quick and simple administration, crucial factors in emergency situations.
Milton Boyer, CEO of Kindeva, emphasized the urgency of their mission: "Our nasal drug delivery team has created a nasal spray that is quick and simple to administer, and which has the potential to prevent unnecessary overdoses across the United States."

Public Health Impact

The launch of REZENOPY® comes at a critical time as opioid-related fatalities continue to rise nationwide. Scienture has outlined plans to collaborate with healthcare professionals, policymakers, and advocacy groups to enhance awareness and accessibility of this life-saving intervention.
"This collaboration is not just about expanding our portfolio; it's about making a real difference in the fight against opioid addiction," explained Shankar Hariharan, Ph.D., CEO of Scienture, LLC. "By working alongside public health agencies and community organizations, we will drive meaningful change and save lives."

Safety and Storage Considerations

Healthcare providers should note that REZENOPY® requires specific storage conditions between 2°C to 25°C (36°F to 77°F), with protection from light and extreme temperatures. The medication carries important safety considerations, including the potential for precipitating opioid withdrawal in dependent patients and the need for continued monitoring due to the possibility of returning respiratory depression after initial treatment.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Nexus Pharmaceuticals Secures FDA Approval for Tacrolimus Injectable Formulation

Nexus Pharmaceuticals has received FDA approval for Tacrolimus Injection, expanding treatment options for organ transplant patients requiring immunosuppression.
The injectable formulation provides an alternative delivery method for patients who cannot take oral tacrolimus, addressing an important medical need in transplant care.

FDA Approves Opvee, First Intranasal Nalmefene Therapy for Opioid Overdose

The FDA has granted approval for Opvee, the first intranasal nalmefene therapy for emergency treatment of opioid overdose in patients 12 and older. Developed by Opiant Pharma and now owned by Indivior, the drug offers a longer-acting alternative to existing naloxone treatments amid the ongoing opioid crisis that claimed over 103,000 lives in the past year.

Xanomeline/Trospium Chloride (COBENFY™) Approved for Schizophrenia Treatment

Xanomeline/trospium chloride (COBENFY™) has received its first approval in the USA for treating schizophrenia in adults, marking a new approach in psychiatric medication.
The oral, fixed-dose combination targets muscarinic acetylcholine receptors, with xanomeline acting as an agonist at M1 and M4 receptors in the brain.

Neurocrine Biosciences' Crinecerfont Receives FDA Approval for Congenital Adrenal Hyperplasia

The FDA has approved Crinecerfont, developed by Neurocrine Biosciences, as the first drug in decades for congenital adrenal hyperplasia (CAH).
Crinecerfont is designed to reduce elevated androgen levels in individuals with CAH, addressing a critical unmet need in current treatment.

NurExone's ExoPTEN Receives Orphan Medicinal Product Designation from EMA

NurExone's ExoPTEN therapy has been granted Orphan Medicinal Product Designation by the European Medicines Agency (EMA).
The EMA designation provides incentives such as market exclusivity, grants, and reduced-cost scientific advice for NurExone.

Unicycive's OLC Receives FDA Acceptance for Hyperphosphatemia NDA

The FDA has accepted Unicycive Therapeutics' New Drug Application for Oxylanthanum Carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis.
The FDA has set a PDUFA target action date of June 28, 2025, for OLC, a next-generation lanthanum-based phosphate binding agent.

FDA Approves Abuse-Deterrent Oxycodone Tablets (Roxybond) for Severe Pain Management

The FDA has approved Roxybond (oxycodone hydrochloride) immediate-release 10 mg tablets, developed by Protega Pharmaceuticals, for managing severe pain where alternative treatments are inadequate.
Roxybond features SentryBond technology, making the tablets more difficult to manipulate for misuse, even with chemical extraction or physical alteration.

Cenyx Biotech's CX213 Receives FDA IND Approval for Phase 1 Trial in Subarachnoid Hemorrhage

Cenyx Biotech received FDA IND clearance for CX213, a nanozyme-based anti-inflammatory drug, to enter Phase 1 trials.
CX213 is designed as an emergency treatment for subarachnoid hemorrhage (SAH), addressing a critical unmet need.

FDA Approves Genentech's Ocrevus Zunovo as First Twice-Yearly Subcutaneous MS Treatment

The FDA has approved Ocrevus Zunovo, a subcutaneous injection, for relapsing and primary progressive multiple sclerosis.
Ocrevus Zunovo is the first and only twice-a-year, 10-minute subcutaneous treatment option for both forms of MS.

FDA Approves Zurnai Auto-Injector for Opioid Overdose Emergency Treatment

The FDA has approved Zurnai (nalmefene hydrochloride) auto-injector for emergency treatment of known or suspected opioid overdose in adults and pediatric patients aged 12 years and older.
Zurnai delivers 1.5 mg of nalmefene hydrochloride per actuation and is intended for immediate administration in settings where opioids may be present, but it is not a substitute for emergency medical care.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy